Bristol Myers scores another Opdivo approval, as Merck converts AA to full approval for Keytruda in MCC

Bris­tol My­ers Squibb on Fri­day nabbed an­oth­er ap­proval for its block­buster can­cer treat­ment Op­di­vo.

The drug was ap­proved to treat pa­tients ages 12 and old­er with com­plete­ly re­sect­ed stage IIB or IIC melanoma based on pos­i­tive re­sults from the Phase III Check­Mate -76K tri­al, which showed a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in re­cur­rence-free sur­vival com­pared to a place­bo. Op­di­vo’s new ap­proval comes as Mer­ck’s Keytru­da al­so gar­nered a win from the FDA — a full ap­proval for the treat­ment of Merkel cell car­ci­no­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.